FDA-Approved Macaque Target Evidence Report
Provenance: User-pasted report delivered via Hermes WebUI, 2026-09-12. AI-generated (ChatGPT conversation excerpt; includes an unresolved sandbox: docx link). Content: FDA-approved drugs where cynomolgus/rhesus macaque work contributed pharmacology, target validation, efficacy, or translational dose/PD evidence beyond GLP toxicology. Verbatim text follows; citations and key numbers were web-verified during ingest — see macaque-target-validation for per-case status and caveats.
Yes. Once the criterion is tightened to “macaque work contributed meaningful pharmacology, target validation, efficacy, or translational dose/PD evidence—not merely GLP toxicology”, there are substantially more examples than IL-31.
I found a high-confidence set of 12 FDA-approved drugs across 8 target/pathway classes, plus a second group where macaques were clearly pharmacologically relevant but the decisive efficacy model was a rodent surrogate.
The strongest examples
| FDA-approved drug | Target | Macaque contribution | Strength |
|---|---|---|---|
| Nemolizumab (NEMLUVIO) | IL-31RA | Cynomolgus IL-31 induced scratching; a single 1 mg/kg dose suppressed scratching for ~56 days | Very strong |
| Mepolizumab (Nucala) | IL-5 | Ascaris-sensitized cynomolgus monkeys: reduced blood eosinophilia and pulmonary eosinophilic inflammation | Very strong |
| Benralizumab (Fasenra) | IL-5Rα | Cynomolgus eosinophil pharmacology; profound depletion of circulating and marrow eosinophils; asthma-related activity | Very strong |
| Tocilizumab (Actemra) | IL-6R | Cynomolgus collagen-induced arthritis; reduced joint swelling and neutrophilic inflammation | Strong |
| Erenumab (Aimovig) | CGRP receptor | Dose-dependent inhibition of capsaicin-induced dermal blood flow in cynomolgus monkeys | Strong |
| Fremanezumab (Ajovy) | CGRP | Functional inhibition of capsaicin/CGRP-mediated vasodilation in cynomolgus monkeys | Strong |
| Galcanezumab (Emgality) | CGRP | Cynomolgus dermal blood-flow assay; ~87%, 71%, 63% inhibition at Days 1, 15, 29 | Strong |
| Eptinezumab (Vyepti) | CGRP | Monkey dermal blood-flow models demonstrated functional pathway blockade | Strong |
| Ranibizumab (Lucentis) | VEGF-A | Cynomolgus laser-induced CNV; reduced severe vascular leakage | Very strong |
| Aflibercept (Eylea) | VEGF-A/VEGFR decoy | Cynomolgus CNV; prevented severe leakage and regressed established active CNV | Very strong |
| Faricimab (Vabysmo) | VEGF-A + ANG-2 | Cynomolgus CNV; reduced CNV/retinal injury and tested the added ANG-2 mechanism | Strong |
| Inclisiran (Leqvio) | PCSK9 | Cynomolgus monkeys: exposure-dependent PCSK9 suppression correlated with LDL-C reduction | Strong |
The nemolizumab case is indeed one of the cleanest examples. The cynomolgus model generated the relevant phenotype with IL-31 itself, and the therapeutic antibody reversed it, giving a very direct target → primate phenotype → therapeutic blockade chain. (PubMed)
Particularly compelling examples outside IL-31
IL-5 / mepolizumab is probably the best parallel. The original primate work showed that mepolizumab reduced both circulating eosinophilia and eosinophil recruitment into the airways of Ascaris-sensitized cynomolgus monkeys, with effects lasting roughly six weeks. FDA’s review independently documents reductions in peripheral and pulmonary eosinophilia in cynomolgus monkeys. (PubMed)
IL-5Rα / benralizumab is also unusually strong because the NHP experiment demonstrates a pharmacological mechanism different from ligand neutralization: receptor-mediated eosinophil depletion. FDA documentation establishes cynomolgus IL-5Rα as a pharmacologically relevant target, and the preclinical literature reports marked depletion of eosinophils and their precursors. (FDA Access Data)
IL-6R / tocilizumab gives you a proper primate inflammatory disease model. Cynomolgus collagen-induced arthritis was used for pharmacodynamic testing, and published experiments found reduced joint swelling and neutrophil infiltration. The FDA review also documents the cynomolgus pharmacodynamic program, although anti-drug antibodies complicated interpretation of dose-response. (FDA Access Data)
The CGRP class is fascinating because it gives you four FDA-approved drugs with convergent NHP functional pharmacology. Erenumab produced dose-dependent inhibition of capsaicin-induced dermal blood flow in cynomolgus monkeys; fremanezumab, galcanezumab and eptinezumab likewise had monkey vascular assays demonstrating functional CGRP blockade. (FDA Access Data)
The VEGF/CNV group may be the strongest argument of all for a translational role of macaques. Ranibizumab, aflibercept and faricimab were tested in the cynomolgus laser-induced choroidal neovascularization model, where the endpoint is anatomically and pathophysiologically close to the human ocular disease. Ranibizumab reduced severe leakage; aflibercept prevented severe CNV leakage and could regress established lesions; faricimab tested the added ANG-2 mechanism in the same primate paradigm. (FDA Access Data)
PCSK9/inclisiran is a different but very persuasive form of NHP validation. FDA’s pharmacology package reports dose/exposure-dependent suppression of circulating PCSK9 in cynomolgus monkeys, with suppression correlated with reductions in LDL-C and total cholesterol. A published NHP study subsequently reported roughly 66–85% PCSK9 reduction and 65–92% LDL-C reduction under the tested regimen. (FDA Access Data)
An important distinction: “macaque involved” is not the same as “macaque validated the target”
I think this distinction will be particularly important for the argument you are developing.
There is a second tier of FDA-approved drugs where the cynomolgus monkey was clearly important because the therapeutic target cross-reacted, allowing PK/PD, receptor binding or species selection—but where the actual efficacy experiment was performed in a mouse surrogate.
Examples include:
- Tezepelumab — TSLP
- Secukinumab / ixekizumab — IL-17A
- Guselkumab / tildrakizumab / risankizumab — IL-23p19
- Omalizumab — IgE
- Liraglutide — GLP-1R
- Brolucizumab — VEGF-A
These are real NHP contributions, but I would not put them in the same evidentiary category as nemolizumab, mepolizumab or cynomolgus CNV. For example, tezepelumab binds cynomolgus TSLP with high affinity and cynomolgus was the relevant species, but its decisive in-vivo efficacy program relied on a mouse anti-mouse TSLP surrogate. (FDA Access Data)
Likewise, some biologics illustrate the opposite situation. Eculizumab/C5 could not exploit macaque target pharmacology because animal C5 is insufficiently cross-reactive, while dupilumab/IL-4Rα required surrogate approaches rather than direct macaque efficacy. (BPS Journals)
Two additional cases worth keeping, but labelled carefully
There are also very impressive macaque examples from later indication development, rather than the evidence underlying the original approval:
Maraviroc / CCR5: rhesus macaque SHIV studies have provided functional target and prophylactic-efficacy evidence, but that work is better described as subsequent HIV prevention/microbicide development than as the core evidence behind the original systemic HIV treatment approval.
Lenacapavir / HIV-1 capsid: rhesus/pigtail macaque challenge studies have shown striking protection against simian-tropic HIV and were important in later PrEP development. Again, the distinction matters: much of this work followed the drug’s original treatment approval rather than establishing the original approval package. (ScienceDirect)
My ranking for a “NHPs enabled human-relevant target validation” argument
If the eventual purpose is a paper, grant, investor deck, or company rationale arguing that NHPs can provide a human-relevant validation layer that rodents often cannot, I would lead with:
1. VEGF-A → ranibizumab/aflibercept The cynomolgus CNV model is probably the cleanest example of a primate disease phenotype closely resembling the clinical target.
2. IL-31RA → nemolizumab Especially elegant because the target ligand itself produces the primate behavioral phenotype and the drug reverses it.
3. IL-5 / IL-5Rα → mepolizumab/benralizumab Strong direct primate immunological pharmacology.
4. CGRP → erenumab/fremanezumab/galcanezumab/eptinezumab Perhaps the strongest class-level demonstration: multiple independently developed approved drugs converged on functional macaque pharmacology.
5. IL-6R → tocilizumab A bona fide primate inflammatory disease model.
6. PCSK9 → inclisiran An excellent quantitative molecular-target → circulating biomarker → clinically meaningful phenotype bridge.
I prepared a detailed research report with the evidence tiers, case-by-case analysis, boundary cases, counterexamples, and source inventory:
Download the full FDA-approved macaque target evidence report
One particularly interesting next step would be to expand this into a systematic table of ~50–100 FDA-approved drugs, separating “macaque efficacy/target validation,” “macaque PK/PD,” and “macaque toxicology only.” That would make it much more powerful as quantitative evidence for the value of NHPs in CNS and drug discovery.